COLL Collegium Pharmaceutical Inc.

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences

STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

Leerink Partners Global Healthcare Conference

Monday, March 9, 2026

Miami, FL

Jefferies Biotech on the Beach Summit

Tuesday, March 10, 2026

Miami, FL

The Citizens Life Sciences Conference

Tuesday, March 10, 2026

Miami, FL

Barclays 28th Annual Global Healthcare Conference

Fireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ET

Miami, FL

A live webcast of the fireside chat will be available via the Investors section of the Company's website: . A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

About Collegium Pharmaceutical, Inc.

Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at .

Investor Contacts:

Ian Karp

Head of Investor Relations

Danielle Jesse

Director, Investor Relations

Media Contact:

Jessica Cotrone

Senior Vice President, Corporate Communications & Corporate Affairs



EN
02/03/2026

Underlying

COLLCollegium Pharmaceutical Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Collegium Pharmaceutical Inc.

Free Trial
COLL Collegium Pharm...

Collegium Pharmaceutical Inc: 1 director

A director at Collegium Pharmaceutical Inc sold 49,976 shares at 40.408USD and the significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...

COLL COLLEGIUM PHARMACEUTICAL INC.
6h / 55m 6h / 55m 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Present New Real-World Data at PainConnect 2026

Collegium to Present New Real-World Data at PainConnect 2026 STOUGHTON, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the American Academy of Pain Medicine (AAPM)’s Annual Meeting, taking place in Salt Lake City, Utah from March 5-8, 2026. The presentations highlight real-world clinical insights from Collegium’s pain portfolio and reflect the Company’s continued focus on generating evidence that helps inform everyday practice. “U...

19h / 16m 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Em...

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community – Paris Hilton shares her personal ADHD journey and encourages others to see ADHD in a new light – –Together, Paris and Collegium are reframing common stereotypes and highlighting experiences that are often part of living with ADHD, including the importance of talking to a doctor and finding an individualized treatment plan –          Credit: Ashley Osborn STOUGHTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasd...

March 3, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium to Participate in Upcoming Investor Conferences

Collegium to Participate in Upcoming Investor Conferences STOUGHTON, Mass., March 02, 2026 (GLOBE NEWSWIRE) --  (Nasdaq: COLL) today announced that its management will participate in the following investor conferences: Leerink Partners Global Healthcare ConferenceMonday, March 9, 2026Miami, FL Jefferies Biotech on the Beach SummitTuesday, March 10, 2026Miami, FL The Citizens Life Sciences ConferenceTuesday, March 10, 2026Miami, FL Barclays 28th Annual Global Healthcare ConferenceFireside Chat Date and Time: Wednesday, March 11, 2026 at 9:00 a.m. ETMiami, FL A live webcast of the fire...

March 2, 2026 1 EN
 PRESS RELEASE
Free
COLL Collegium Pharm...

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results – Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch